Tomoyuki Endo

Title: Tomoyuki Endo: Innovator in Cancer Detection

Introduction

Tomoyuki Endo is a prominent inventor based in San Diego, California. He has made significant contributions to the field of cancer detection, particularly in the identification and treatment of lymphomas and adenocarcinomas. His innovative work has the potential to improve patient outcomes and advance cancer research.

Latest Patents

Tomoyuki Endo holds a patent for "Methods and compounds for lymphoma cell detection and isolation." This patent includes compositions comprising a purified and/or isolated antibody, humanized antibodies, precipitates, and anti-sera that specifically bind to or are directed against the ROR1 protein. These compositions are designed for detecting ROR1 in samples from subjects suspected or known to contain cancer cells. The ROR1 antibodies are particularly useful in identifying and treating lymphomas and adenocarcinomas. Additionally, the patent provides vaccines and related methods for protecting subjects against diseases involving ROR1 expression, as well as human anti-sera that effectively disrupt interactions between Wnt5a protein and ROR1, which contribute to the survival of certain cancer cells, such as CLL cells.

Career Highlights

Tomoyuki Endo is affiliated with the University of California, where he continues to engage in groundbreaking research. His work has garnered attention for its potential applications in clinical settings, particularly in oncology.

Collaborations

Tomoyuki Endo has collaborated with notable colleagues, including H Elizabeth Broome and Liguang Chen. These partnerships have enhanced the scope and impact of his research efforts.

Conclusion

Tomoyuki Endo's innovative contributions to cancer detection and treatment exemplify the importance of research in improving healthcare outcomes. His work continues to inspire advancements in the field of oncology.